Cellares

Cellares is a pioneering Integrated Development and Manufacturing Organization (IDMO) that is revolutionizing the production of the life-saving cell therapies of the 21st century. With an Industry 4.0 approach, the company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to these vital treatments. Their innovative Cell Shuttle merges all the necessary technologies for the entire manufacturing process into a flexible and high-throughput platform, offering end-to-end automation. These Cell Shuttles will be deployed in Cellares' Smart Factories globally, addressing the total patient demand for cell therapies at a global scale. Collaborating with Cellares empowers academics, biotechs, and pharma companies to hasten drug development and scale out manufacturing, reduce process failure rates, minimize manufacturing costs, and meet the global patient demand. Founded in 2019, Cellares is headquartered in South San Francisco, California, and operates its commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. The company has garnered significant support from world-class investors and has successfully secured over $355 million in funding, including the recent $255.00M Series C investment on 23 August 2023. Notably, this investment round saw participation from 8VC, DFJ Growth, Eclipse Ventures, Decheng Capital, Koch Disruptive Ventures, Willett Advisors, and Bristol-Myers Squibb. With its innovative technologies, strategic partnerships, and substantial financial backing, Cellares is well-positioned to drive forward the advancement and accessibility of life-saving cell therapies.